Introduction and rationale {#Sec1}
==========================

Early-stage breast cancer is traditionally treated with an initial surgery such as lumpectomy or mastectomy followed by subsequent adjuvant therapy, including radiotherapy, chemotherapy, and hormone therapy \[[@CR1], [@CR2]\]. Numerous studies have investigated the use of preoperative (neoadjuvant) hormonal therapy or chemotherapy prior to surgical intervention, with the goals to improve surgical outcome and obtain long-term disease-free survival (DFS) (see Table [1](#Tab1){ref-type="table"}). The National Surgical Adjuvant Breast and Bowel Project B-18 trial demonstrated that doxorubicin and cyclophosphamide administered as neoadjuvant or adjuvant therapy had equivalent outcomes in terms of both DFS and overall survival (OS) \[[@CR3]\]. Adding a taxane in the B-27 trial significantly reduced the local recurrence rate but did not significantly increase DFS or OS \[[@CR4]\]. Importantly, neoadjuvant chemotherapy has been shown to increase the rate of breast-conserving surgery (BCS) without adversely affecting DFS or OS \[[@CR3], [@CR5]--[@CR7]\]. Therefore, neoadjuvant chemotherapy has become the standard treatment approach for locally advanced breast cancer and an accepted option for patients with primary operable disease \[[@CR8]\]. Table 1Aims of neoadjuvant therapy in different breast cancer populationsPopulationAimsTreatment optionLocally advanced breast cancerPrimary: to improve surgical optionsFit and healthy patients: chemotherapySecondary: to obtain freedom from disease, to gain information on tumor responseUnfit patients with hormone-sensitive disease: endocrine treatmentOperable breast cancer and candidates for adjuvant chemotherapyPrimary: to obtain freedom from diseaseChemotherapy ± OFS and/or AIsSecondary: to improve surgical options, to gain information on tumor responseSequence versus combination\
Longer versus shorterOperable breast cancer and candidates for adjuvant endocrine treatment alonePrimary: to improve surgical optionsEndocrine treatment longer versus shorterSecondary: to gain information on tumor responseTamoxifen versus AIsReprinted from \[[@CR8]\] with permission from the American Society of Clinical Oncology*AIs* aromatase inhibitors, *NST* neoadjuvant systemic therapy, *OFS* ovarian function suppression

Significant tumor reduction from neoadjuvant chemotherapy occurs in only subsets of breast cancer, however. For example, patients with estrogen receptor-negative (ER−), high-grade, and highly proliferative tumors appear to benefit the most from neoadjuvant chemotherapy \[[@CR9]--[@CR11]\]. In contrast, significantly lower response rates have been reported in patients with ER+ tumors in neoadjuvant chemotherapy trials \[[@CR12]--[@CR15]\]. The German Breast Group demonstrated that the pathologic complete response (pCR) rates were 6.2 versus 22.8% for ER+ and ER− tumors, respectively (odds ratio 3.23, 95% confidence intervals \[CIs\] 1.91, 5.46; *P* = 0.0001) \[[@CR12]\]. Recent studies indicate that the sensitivity to chemotherapy is likely determined by the underlying gene expression pattern and the molecular subtype of the tumor \[[@CR16], [@CR17]\]. The luminal subtype categorized by gene expression profiling, which encompasses most of the ER+ tumors, is less responsive to preoperative chemotherapy than the basal-like and human epidermal growth factor receptor 2-positive (HER2+) cancer. In addition, neoadjuvant chemotherapy is associated with substantial toxicity that may limit its clinical benefits and acceptability, especially in the elderly patient population \[[@CR13], [@CR18]--[@CR20]\]. Thus, there is great need for effective alternatives to cytotoxic chemotherapy in hormone-responsive locally advanced breast cancer.

Endocrine treatment is an attractive alternative to chemotherapy as neoadjuvant or primary systemic therapy for women with hormone-responsive primary breast tumors \[[@CR21]--[@CR23]\]. A study comparing neoadjuvant endocrine therapy with exemestane versus chemotherapy in 152 patients with ER+/progesterone receptor-positive (PgR+) breast cancer found that while efficacy outcomes were comparable in the two groups, chemotherapy treatment was significantly more toxic, confirming that endocrine therapy could be used as an alternative to chemotherapy in older women \[[@CR24]\]. Early studies of primary tamoxifen as an alternative to surgery were conducted in older women with hormone-responsive breast cancer who were unfit for chemotherapy \[[@CR23], [@CR25]--[@CR27]\]. While these studies demonstrated a reduction in tumor size with primary tamoxifen, long-term local disease control was found to be poor. The omission of primary surgery resulted in an increased rate of progression, therapeutic intervention, and mortality \[[@CR28]\]. Thus, primary tamoxifen treatment is indicated for only the most frail, medically ill, or noncompliant patients \[[@CR29]\]. Although primary therapy with tamoxifen was found to be well-tolerated, adverse effects were reported including hot flushes, skin rash, vaginal discharge, breast pain, sleepiness, headache, vertigo, itching, hair loss, cystitis, acute thrombophlebitis, nausea, and indigestion \[[@CR29]\]. Furthermore, more serious adverse effects, such as an increased risk of endometrial cancer and thromboembolic events, have been reported in large trials of adjuvant tamoxifen \[[@CR30]\].

In view of the limitations of tamoxifen as a single modality treatment, attention has switched to the neoadjuvant use of endocrine therapy to increase the rate of breast conservation \[[@CR21]\]. Data from preclinical models \[[@CR31]\] and clinical studies in advanced breast cancer \[[@CR32]\] predict that aromatase inhibitors (AIs) may be more effective than tamoxifen in the neoadjuvant setting. Furthermore, preclinical and clinical evidence suggests that letrozole may be the most effective AI in this setting \[[@CR33]--[@CR35]\]. In postmenopausal women with endocrine-responsive locally advanced or metastatic breast cancer, first-line treatment with letrozole was shown to be significantly more effective than tamoxifen in terms of response rate (overall response rate \[ORR\], 30 vs. 20%, *P* = 0.0006) and time to disease progression (41 vs. 26 weeks) \[[@CR32]\]. A phase 1--2 pilot study showed a clinical response rate of 88% (21/24 patients) in postmenopausal women with ER+ locally advanced breast cancer treated with letrozole for 3 months prior to surgery \[[@CR36]\]. All patients in the study were eligible for breast conserving surgery following neoadjuvant letrozole.

A large multinational trial, P024, was designed to assess the efficacy of neoadjuvant letrozole compared with tamoxifen in postmenopausal women with hormone receptor-positive (HR+) breast cancer who were ineligible for breast-conserving surgery \[[@CR21]\]. The clinical objectives of the trial were to compare response rates and surgical outcomes between the two treatment arms. In addition, the trial provided the opportunity to conduct prospective biomarker studies to explore the biologic basis for response to neoadjuvant endocrine therapy \[[@CR37]\]. This review describes the results of the P024 study and the follow-up biomarker studies, focusing on the treatment implications in the neoadjuvant setting.

Trial design and patients {#Sec2}
=========================

PO24 was a multinational, randomized, double-blind controlled trial comparing letrozole and tamoxifen in postmenopausal women with hormone-responsive primary invasive breast cancer who were not eligible for breast-conserving surgery \[[@CR21]\]. The trial was conducted in 55 centers in 16 countries between March 1998 and August 1999. Local ethics review boards approved the protocol and all patients gave written informed consent before study enrollment.

Randomized clinical trial design {#Sec3}
--------------------------------

Patients were randomly assigned to receive letrozole 2.5 mg or tamoxifen 20 mg administered orally once daily for 4 months prior to scheduled surgery \[[@CR21]\]. Patients were considered to have completed the study when they had received 4 months of treatment and had been assessed for surgery. Following surgery, patients were treated at the investigator's discretion and were followed for 5 years for local recurrence, distant metastasis, and survival.

Patient population {#Sec4}
------------------

A total of 337 postmenopausal women were enrolled into the trial, and 324 were included in the intent-to-treat population (see Fig. [1](#Fig1){ref-type="fig"}). Eligible patients were postmenopausal women with untreated, primary HR+ (≥10% nuclear staining for ER or PgR) invasive breast tumors (stages T2--4a--c, N0--2, M0). The minimum tumor size was ≥3 cm, and all patients were considered inoperable or ineligible for breast-conserving surgery, mostly because of a non-favorable ratio tumor size/breast size. Exclusion criteria included previous exposure to AIs, uncontrolled endocrine or cardiac disease, bilateral or inflammatory breast cancer, distant metastasis, and other malignant disease. In addition, administration of other cancer treatment or hormone replacement therapy was not allowed during study participation. Fig. 1Patient disposition \[[@CR21]\]

Trial end points {#Sec5}
----------------

The primary end point was ORR, defined as the percentage of patients in each treatment arm with a complete response (CR) or a partial response (PR) as determined by breast palpation \[[@CR21]\]. Response categories were CR, PR, no change, progressive disease, or not assessable/not evaluable. The secondary end points were the percentage of patients who underwent breast-conserving surgery and the response rate (CR + PR) determined at 4 months by mammography and by ultrasound \[[@CR21]\]. Safety was assessed and adverse events graded according to the National Cancer Institute Common Toxicity Criteria.

Correlative science studies {#Sec6}
---------------------------

In parallel, studies were conducted in which tumor biopsies and blood samples were taken from all patients prior to the initiation of therapy and at the end of treatment to generate a database from which changes in molecular markers could be assessed \[[@CR37]--[@CR41]\]. These studies were prospectively designed to assess the biological basis for letrozole efficacy. The specific objectives of the biomarker sub-studies were as follows:To confirm ER and PgR status in a central laboratory. ER and PgR were determined using immunohistochemistry (IHC) performed on pretreatment biopsies; the criterion for minimal ER positivity was 10% positive cells \[[@CR37]\]. The Allred histopathological score was applied to further assess the level of ER and PgR expression in both the baseline and surgical specimens \[[@CR42]\].To explore relationships between ER and PgR expression levels and response to treatment \[[@CR37]\].To examine the relationship between the expression of HER1 and HER2 and the likelihood of primary response \[[@CR37]\]. Previous studies have shown that HER2 overexpression may be a predictor of tamoxifen resistance \[[@CR43], [@CR44]\], and HER1 has also been linked with endocrine therapy resistance \[[@CR45]\]. HER2 IHC was initially scored as 0/+ (negative) or ++/+++ (positive or overexpressed) \[[@CR46]\]. Since fluorescent in situ hybridization**(**FISH) testing has replaced IHC as the gold standard for HER2 assessment, the P024 tumor bank was reassessed using HER1 and HER2 FISH probes, and these data on HER2 gene amplification status were supplemented with 106 tumor samples \[[@CR40]\]. Pre- and post-treatment tumor biopsy samples were also analyzed for ER and several indices of ER function, including PgR and trefoil factor 1 (TFF1), HER1 and HER2, and the proliferation marker Ki67 \[[@CR38]\].To assess gene expression profiling as a means to further investigate the transcriptional programs that underlie resistance and sensitivity to estrogen deprivation \[[@CR39]\]. Gene expression (mRNA) profiles were collected from the tumor biopsies collected prior to surgery, at 1 month of treatment, and at surgery. The analysis was done using an Affymetrix U 133 subA Gene Chip.To measure aromatase expression in tumors before and after 4 months of letrozole or tamoxifen treatment. Aromatase is the key enzyme responsible for estrogen biosynthesis and is present in about 70% of tumors. IHC was performed with a monoclonal aromatase antibody (677) on trial samples prior to and following letrozole or tamoxifen treatment (*n* = 185); scoring was measured as a proportion of immuno-positive cells and their intensity of reactivity in malignant epithelial, stromal, adipose, and normal compartments \[[@CR41]\].

Efficacy {#Sec7}
========

In the intent-to-treat population, 154 patients received letrozole and 170 received tamoxifen. Similar proportions of patients in the letrozole and tamoxifen groups had inoperable tumors (13 and 14%, respectively). Other baseline characteristics were also well-balanced for age, race, HR status, and tumor/nodal stage of disease. More patients in the tamoxifen group (*n* = 41) discontinued treatment than in the letrozole arm (*n* = 23). The main reason for premature discontinuation was disease progression.

Clinical response and breast-conserving surgery {#Sec8}
-----------------------------------------------

Letrozole was consistently superior to tamoxifen for primary and secondary efficacy end points \[[@CR21]\]. The ORR was 55% for letrozole versus 36% for tamoxifen (*P* \< 0.001). Median time to response was 66 days in the letrozole group and 70 days in the tamoxifen group. The odds ratio for achieving CR + PR was more than doubled with letrozole (2.23, 95% CI 1.43, 3.50; *P* = 0.0005). In terms of clinical progression, 12% of patients on letrozole and 17% on tamoxifen progressed, while 24% of letrozole- and 35% of tamoxifen-treated patients had stable disease. Letrozole was also shown to be significantly more effective than tamoxifen when response rates were assessed by mammography (34 vs. 16%, respectively; *P* \< 0.001) and ultrasound (35 vs. 25%, respectively; *P* = 0.042).

The proportion of patients able to undergo breast-conserving surgery was significantly higher in the letrozole group than in the tamoxifen group (45 vs. 35%, respectively; *P* = 0.022). Of note, the odds ratio for breast-conserving surgery was 4.56 (*P* = 0.0001) for patients presenting with T2 tumors compared with all other T stages. The only other factor that increased the odds of undergoing breast-conserving surgery was treatment with letrozole (odds ratio 1.71, *P* = 0.03).

ER and PgR {#Sec9}
----------

A supportive analysis of clinical efficacy data conducted in patients with centrally confirmed ER+ or PgR+ tumors also showed that outcomes were significantly improved with letrozole (*n* = 124) compared with tamoxifen (*n* = 126) \[[@CR37]\]. In this subgroup, the ORR was 60% for letrozole versus 41% for tamoxifen (*P* = 0.004), and breast-conserving surgery was performed in 48 versus 36%, respectively (*P* = 0.036).

There was a linear relationship between ER Allred expression scores and response rates to both letrozole and tamoxifen (see Fig. [2](#Fig2){ref-type="fig"}). Tumors with low ER expression were still responsive to letrozole but not to tamoxifen \[[@CR37]\]. Of note, letrozole response rates were numerically superior to tamoxifen response rates in every ER Allred category from three to eight, indicating that letrozole is more effective than tamoxifen regardless of the level of ER expression \[[@CR37]\]. This finding is important, because of all the AIs, only letrozole has demonstrated clear ORR superiority over tamoxifen in ER-poor tumors. When the effects of letrozole and anastrozole on tumors with low ER values (Allred scores 2--5) were compared in the neoadjuvant setting, only letrozole achieved a significant reduction in cell proliferation in ER-poor tumors \[[@CR35]\]. Fig. 2Clinical response rate versus estrogen receptor (ER) Allred score for letrozole and tamoxifen. The *P*value for a linear logistic model was 0.0013 for letrozole and 0.0061 for tamoxifen according the Wald test. In this analysis, ER−, PgR+ cases (determined by conventional cut points) were excluded. Reprinted from \[[@CR37]\] with permission from the American Society of Clinical Oncology

Letrozole, but not tamoxifen, significantly reduced the expression of estrogen-regulated proteins PgR and TFF1 \[[@CR38]\]. Average tumor PgR expression decreased dramatically on letrozole treatment (*P* = 0.0001), and only 4.4% of surgical specimens exhibited an Allred score of between six and eight for PgR expression. The significant decrease in PgR expression with letrozole remained significant in the ER+, HER2+ subpopulation. In contrast, changes in PgR expression with tamoxifen therapy were not consistent, with both increases and decreases in expression frequently observed in the overall and ER+, HER2+ subpopulations. Analysis of changes in TFF1 produced similar conclusions, with letrozole markedly reducing expression (*P* = 0.0001) and tamoxifen producing no overall trend in either direction.

HER1/HER2 and response {#Sec10}
----------------------

Approximately 15% of tumors were ER+ and overexpressed both HER1 and HER2. The response rate in this patient subgroup was significantly higher with letrozole than with tamoxifen (88 vs. 21%) \[[@CR37]\]. The odds ratio for response to letrozole versus tamoxifen was 28 (95% CI 4.5, 177; *P* = 0.0004). Letrozole was equally effective for HER1/HER2+ and HER1/HER2− tumors, whereas tamoxifen was significantly less effective in HER2+ compared with HER2− tumors (*P* = 0.045). These data suggest that although HER1 and HER2 status might not be the only explanation for the superiority of letrozole over tamoxifen, overcoming resistance pathways associated with HER1 and HER2 expression is a significant component of the improvement in outcomes associated with letrozole treatment observed in this clinical trial. FISH analysis of tumor samples confirmed the clinical efficacy of letrozole in breast cancers with or without HER2 amplification (ORR 71% in both subsets; *P* = 0.98). In contrast, tamoxifen-treated tumors with HER2 gene amplification had lower clinical response rates than tamoxifen-treated HER2− tumors (33 vs. 49%, *P* = 0.49) (see Table [2](#Tab2){ref-type="table"}) \[[@CR40]\]. Table 2Analysis of clinical, ultrasound, and mammogram response data according to HER2 FISH status in letrozole-treated patients and tamoxifen-treated patientsResponse CategoryNo. responsesTotal No. (%)No. responsesTotal No. (%)HER2 FISH-positive Tamoxifen-treated patientsHER2 FISH-negative Tamoxifen-treated patients*P*-value^a^Clinical39 (33)4490 (49)0.49Ultrasound39 (33)2674 (35)0.99Mammography19 (11)2290 (24)0.68HER2 FISH-positive Letrozole-treated patientsHER2 FISH-negative Letrozole-treated patients*P*-value^b^Clinical1217 (71)131185 (71)0.98Ultrasound817 (47)91170 (54)0.61Mammography716 (44)84178 (47)0.79Reprinted from \[[@CR40]\] with permission from the American Society of Clinical Oncology*HER2* human epidermal growth factor receptor 2, *FISH* fluorescence in situ hybridization^a^Fisher test *P*-value^b^Mantel--Haenzel *P*-value

Biomarkers of tumor proliferation {#Sec11}
---------------------------------

Letrozole inhibited tumor proliferation, measured by the biomarker Ki67, to a greater extent than tamoxifen (reduction in geometric mean Ki67 level 87 vs. 75%, respectively; *P* = 0.0009). The differences in Ki67 reduction were also observed in ER+, HER1 and/or HER2 overexpressing tumors (88% for letrozole vs. 45% for tamoxifen, respectively; *P* = 0.0018) \[[@CR38]\]. Changes in the percentage of Ki67-positive cells in HER1/2+ tumors treated with letrozole or tamoxifen are shown in Fig. [3](#Fig3){ref-type="fig"}. Fig. 3A box plot of before and after treatment Ki67 values in the estrogen-receptor-positive, human epidermal growth factor receptor (HER) 1/2+ subset. With letrozole (*n* = 15), 11 showed a decrease, one exhibited no change, and three showed an increase, of which only one was \>2-fold (0.1--0.3%). With tamoxifen (*n* = 17), ten showed a decrease and seven an increase, of which three were relatively dramatic (9.5--22.7, 20.9--40.7, and 0.1--17.3%). Reprinted from \[[@CR38]\] with permission from the American Association for Cancer Research

More recently, it was found that HER2 FISH-positive tumors showed higher histologic grade (*P* = 0.009), higher pretreatment Ki67 (*P* = 0.005), and less Ki67 suppression after letrozole when compared with HER2 FISH-negative tumors (*P* = 0.0001) \[[@CR40]\]. Letrozole significantly decreased the geometric mean Ki67 level in HER2 FISH-negative tumors (from 6.25 \[95% CI 5.16, 7.58%\] to 0.68% \[95% CI 0.53, 0.87%\]; *P* = 0.0001), but the decrease in HER2 FISH-positive tumors was blunted (from 14.73 \[95% CI 9.67, 22.44%\] to 8.1% \[95% CI 4.16, 15.75%\]; not significant). A similar observation for Ki67 was made in a smaller cohort of tamoxifen-treated tumors \[[@CR40]\].

The relationship between cell cycle CR, defined as ≤1% of post-treatment Ki67 staining in the infiltrating component of the tumor, and HER2 status of tumors treated with letrozole was also analyzed \[[@CR40]\]. Significantly more HER2 FISH-negative than FISH-positive tumors met the definition of a cell cycle CR at the time of surgery (60 vs. 12%; *P* = 0.0001). There was a high level of correlation between lack of cell cycle CR and the presence of a positive HER2 FISH test (*P* = 0.0001) for letrozole- and tamoxifen-treated tumors, which is consistent with the conclusion that HER2 gene amplification generates resistance at the level of cell cycle progression regardless of which endocrine therapy is used \[[@CR40]\].

These biomarker findings are discordant with clinical observations that tumor regression is unaffected by HER2 amplification status in patients treated with neoadjuvant letrozole and may imply therapeutic resistance that could manifest later in the clinical course of the disease. Consistent with this finding, Miller and colleagues also reported that neoadjuvant letrozole produces rapid and profound decreases in expression of Ki67 and PgR that do not always correlate with clinical and pathological responses \[[@CR47]\].

Gene expression profiling {#Sec12}
-------------------------

Preliminary gene expression profiling analysis of biopsies taken pretreatment and 1 month post letrozole treatment showed down-regulation of genes involved in DNA replication and synthesis, cell cycle progression, apoptosis suppression, and tissue invasion \[[@CR39]\]. These results illustrate the molecular basis for estrogen-deprivation letrozole therapy which may be useful in the development of predictive models of ER+ breast cancer.

Aromatase {#Sec13}
---------

Sufficient pre- and post-treatment tumor material was available from 171 cases (81 on letrozole and 90 on tamoxifen) from the P024 trial for immunohistochemistry analysis of aromatase protein expression \[[@CR41]\]. Aromatase was detected in all tumor compartments, with the strongest staining observed in malignant epithelial cells. Median aromatase values did not change significantly with letrozole or tamoxifen treatment; however, changes in score did occur in individual cases, with more noticeable effects observed in letrozole-treated patients \[[@CR41]\]. A positive correlation existed between baseline ER and aromatase staining in cancer cells, while a negative correlation was observed between baseline Ki67 and aromatase expression in cancer plus stroma. Baseline aromatase expression did not predict response to letrozole or tamoxifen, or changes in Ki67 induced by treatment. However, negative staining in both stroma and cancer after treatment was strongly associated with fewer cell cycle CR and smaller Ki67 declines with letrozole (but not tamoxifen) treatment \[[@CR48]\].

Safety and duration of therapy {#Sec14}
==============================

P024 demonstrated that letrozole is well-tolerated in the neoadjuvant setting \[[@CR21]\]. There were no major tolerability differences between letrozole and tamoxifen, and adverse effects of a similar nature were seen in 57% of patients in each arm \[[@CR21]\]. The most common treatment-related adverse event was hot flushes, occurring in 20% of patients in the letrozole group and 24% of patients in the tamoxifen group.

The excellent tolerability, predictable pharmacokinetics, and minimal drug--drug interactions \[[@CR49], [@CR50]\] make letrozole a particularly suitable option for older women unable to tolerate or unwilling to accept neoadjuvant chemotherapy and in whom the presence of comorbidities and use of concomitant therapies complicate treatment selection \[[@CR20]\]. The median age of patients in P024 treated with letrozole was 68 years, and 46% of patients were at least 70 years old. The feasibility and safety of letrozole was also reported recently from another trial using letrozole as primary systemic therapy in elderly patients (median age 79 years) with breast cancer \[[@CR51]\]. In addition, letrozole has been successfully administered to elderly patients (median age of the elderly subgroup 75 years; range 70--96 years) in the advanced breast cancer setting \[[@CR52]\].

The favorable safety profile of letrozole also allows for the extension of the neoadjuvant treatment beyond the 4 months used in the P024 trial. In a recent study, 33 postmenopausal women with HR+ breast cancer ineligible for breast-conserving surgery were treated with letrozole for 4 months. Continued administration of letrozole for a further 4 months in responders and patients with stable disease resulted in a statistically significant improvement in tumor size reduction (*P* = 0.039); ORR was 90% in patients receiving preoperative treatment for longer than 4 months compared with 57% in patients receiving treatment up to 4 months \[[@CR53]\].

In another study, 42 patients who were unsuitable for breast-conserving surgery or had refused surgery after responding to initial neoadjuvant therapy with letrozole for 3 months benefited from continuing tumor volume reduction during further letrozole treatment administered for up to 12 months \[[@CR54]\]. The median reductions in tumor volume were 52% (95% CI 37, 62) from 0 to 3 months, 57% (95% CI 26, 100) from 3 to 6 months, and 66% (95% CI 22, 100) from 6 to 12 months. Extending the duration of letrozole also improved the CR rate, which increased from 4/42 patients (9.5%) at 3 months to 12/42 (29%) by 6 months and 8/22 (36%) by 12 months.

Conclusions {#Sec15}
===========

Neoadjuvant therapy with AIs is a safe and effective treatment option for postmenopausal women who are unwilling or unable to undergo surgery or preoperative chemotherapy \[[@CR21], [@CR22], [@CR55]--[@CR57]\]. Letrozole is significantly more effective than tamoxifen in the neoadjuvant setting in terms of ORR and increased rate of breast-conserving surgery \[[@CR21], [@CR55]\].

One of the advantages of using a neoadjuvant strategy is the opportunity to gain information on tumor response early in the course of treatment. Detailed studies correlating clinical response to neoadjuvant therapy with changes in tumor biomarkers and gene expression may ultimately prove useful to tailor therapy for individual patients and to gain a better understanding of the biology of HR+ breast cancer. Correlative studies conducted using tumor samples from P024 have revealed important information about how breast tumors respond to letrozole \[[@CR37]--[@CR40]\]. Letrozole was shown to be significantly more effective than tamoxifen in the inhibition of ER+ tumor proliferation, since letrozole produced a greater reduction in levels of the proliferation biomarker Ki67 \[[@CR38]\]. It has been suggested that a greater suppression in proliferation could lead to greater long-term survival in the adjuvant setting. Preliminary data from the Immediate Preoperative Anastrozole Tamoxifen or Combined with Tamoxifen trial have indicated that short-term changes in Ki67 levels, after 2 and 12 weeks, may be a useful predictive marker for relapse-free survival in patients treated with neoadjuvant AI therapy \[[@CR58]\]. It has also been suggested that changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response \[[@CR59]\].

Correlative studies have also highlighted the complexity of breast cancer biology and revealed discordance between clinical and biomarker responses \[[@CR40]\]. Amplification of HER2 was shown to be associated with a more aggressive breast cancer phenotype and greater resistance to tamoxifen \[[@CR37], [@CR40]\]. Clinical response data from the P024 trial have shown that letrozole is equally effective in HER2+ and HER2− tumors, whereas tamoxifen is less effective in HER2+ tumors \[[@CR37]\]. These data suggest that letrozole could be a superior option to tamoxifen for postmenopausal women with HER2+, HR+ tumors \[[@CR37]\]. However, analysis of proliferation markers has provided evidence of estrogen-independent proliferation of ER+, HER2+ breast cancer despite neoadjuvant letrozole \[[@CR40]\]. It appears that cell-cycle regulation is partially or completely estrogen-independent in the majority of primary tumors showing HER2 gene amplification, and patients with such tumors may eventually develop resistance to adjuvant AI therapy. Novel strategies to delay or overcome hormone resistance are described elsewhere in this supplement, in the article, "Femara and the future."

Gene expression profiling has demonstrated that letrozole targets genes responsible for DNA replication and synthesis, cell cycle progression, apoptosis, and tissue invasion \[[@CR39]\]. Research into genetic profiling is continuing, with the aim of developing clinically relevant predictive models that can accurately classify ER+ disease according to likely response to specific neoadjuvant therapies. Predictive models will improve treatment individualization and help to avoid unnecessary treatment-related toxicity in patients unlikely to benefit from systemic therapies \[[@CR17], [@CR60]\].

The P024 trial has clearly demonstrated the therapeutic superiority of letrozole over tamoxifen for the neoadjuvant management of primary breast cancer. The trial has also provided the oncology community with a validated research setting within which to gain valuable insights into the molecular features of ER+ breast cancer and its treatment that will help shape new therapies in the years to come.

An erratum to this article can be found at <http://dx.doi.org/10.1007/s10549-007-9850-y>
